BioSpace News Archive

SUNRISE, FL / ACCESSWIRE / January 19, 2021 / U.S. Stem Cell, Inc. (OTC PINK:USRM), a leader in the development of proprietary, physician-based, and novel regenerative medicine solutions, is pleased to announce that oral arguments in the case United States v. U.S. Stem Cell Clinic, LLC, et al., took place on January 13, 2021, before the federal Eleventh Circuit Court of Appeals.

InMed’s Michael Woudenberg , Karen Long & Prof. Mauro Maccarrone among Expert Speakers

Signet Healthcare Partners and Bionpharma Inc today announced the sale of CoreRx, a global contract development and manufacturing organization (“CDMO”). Following the sale to private equity firm NovaQuest Private Equity, Signet Healthcare Partners will retain a meaningful equity stake in CoreRx. The terms of the transaction are not disclosed. Based in Clearwater, FL, CoreRx is a leading provider of clinical and commercial CDMO services to a wide ra

Celcuity Inc. (Nasdaq: CELC), a clinical stage biotechnology company utilizing its 3 rd generation companion diagnostics to identify new targeted therapeutic options for cancer patients, announced today that Brian Sullivan, Chairman, Chief Executive Officer, and Co-Founder of Celcuity, will present at the B. Riley Oncology Investor Conference to be held January 20-21, 2021. Mr. Sullivan will present an overview of Celc

Increasing incidences of chronic disorders such as cardiovascular diseases, diabetes, liver and kidney illnesses globally owing to factors like unhealthy lifestyle, stress, obesity, and others have supported the need for a reliable health insurance solution.

Medline and byACRE, a Copenhagen-based designer and producer of advanced mobility products, announced a strategic partnership to meet the growing demand for stylish and functional mobility aids.

Prosetta Biosciences, a San Francisco biotechnology company, has developed novel small-molecule drugs that research indicates are effective not only against the COVID-19 virus, but against other virus families that cause respiratory disease, including influenza and the common cold – without the liability of drug resistance development.

Histogen Inc. (NASDAQ: HSTO), today announced that the U.S. Food and Drug Administration (FDA) has verbally notified the company that it has additional questions about the company’s Investigational New Drug (“IND”) application package for the planned Phase 1/2 clinical trial of HST-003,

Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that it has commenced an underwritten public offering of shares of its common stock.

Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that Christopher Moxham, Ph.D., has been promoted to the role of chief scientific officer